Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
U.K. Fund Supports Dementia Research
by Rick Mullin
March 23, 2015
| A version of this story appeared in
Volume 93, Issue 12
The U.K. government has formed a $100 million venture capital fund to finance dementia research. Investors in the Dementia Discovery Fund include Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly & Co., and Pfizer. The fund intends to comb the global scientific community for promising early-stage research in which to invest. Partners will be sought to move promising work through clinical development. “The fund is a really smart way of bringing together great minds and communally increasing our understanding of dementia,” says Patrick Vallance, head of R&D at GSK, which put $25 million in the fund.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X